Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

Ítems similars

• Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation
  per: Nishimura, Tadashi, et al.
  Publicat: (2021)
• Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer
  per: Hirsh, Vera
  Publicat: (2012)
• Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China
  per: Xiangcheng Li, et al.
  Publicat: (2025-10-01)
• EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
  per: Sonoda, Tomoaki, et al.
  Publicat: (2018)
• Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease
  per: Arulananda, Surein, et al.
  Publicat: (2019)